

NA Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 292 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The North America pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.7% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:

- Rise in prevalence and incidence of pancreatic cancer
- Increase in awareness about the pancreatic cancer diagnostics

Market Players:

Some of the major players operating in the North America pancreatic cancer diagnostics market are:

- Canon Medical Systems ANZ Pty Limited.
- Koninklijke Philips N.V.
- Siemens Healthcare Private Limited
- Grail
- Myriad Genetics, Inc.
- BD
- Abbott

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- FUJIFILM Holdings America Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific
- QIAGEN
- MP BIOMEDICALS
- Laboratory Corporation of America Holdings
- CTK Biotech, Inc.
- Creative Biolabs
- Meridian Life Science, Inc.
- Lee Biosolutions, Inc

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	91
1.1 OBJECTIVES OF THE STUDY	91
1.2 MARKET DEFINITION	91
1.3 OVERVIEW OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET	91
1.4 CURRENCY AND PRICING	94
1.5 LIMITATIONS	94
1.6 MARKETS COVERED	94
2 MARKET SEGMENTATION	98
2.1 MARKETS COVERED	98
2.2 GEOGRAPHICAL SCOPE	99
2.3 YEARS CONSIDERED FOR THE STUDY	100
2.4 DBMR TRIPOD DATA VALIDATION MODEL	101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	104
2.6 MULTIVARIATE MODELLING	105
2.7 MARKET END USER COVERAGE GRID	106
2.8 PRODUCT LIFELINE CURVE	107
2.9 DBMR MARKET POSITION GRID	108
2.10 VENDOR SHARE ANALYSIS	109
2.11 SECONDARY SOURCES	110
2.12 ASSUMPTIONS	110
3 EXECUTIVE SUMMARY	111
4 PREMIUM INSIGHTS	114
4.1 PESTEL ANALYSIS	115
4.2 PORTER'S FIVE FORCES MODEL	116
5 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS	117
6 EPIDEMIOLOGY	119
7 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS	120
8 MARKET OVERVIEW	123
8.1 DRIVERS	125
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER	125
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS	125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	126
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER	126
8.2 RESTRAINTS	127
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS	127
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER	127
8.3 OPPORTUNITIES	128
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER	128
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT	129
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS	129
8.4 CHALLENGES	130
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES	130
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS	130
9 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE	131
9.1 OVERVIEW	132
9.2 IMAGING TEST	135
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN	136
9.2.2 MAGNETIC RESONANCE IMAGING (MRI)	136
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY	136
9.2.2.2 MR ANGIOGRAPHY (MRA)	137
9.2.3 ULTRASOUND	137
9.2.3.1 ABDOMINAL ULTRASOUND	137
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS)	137
9.2.4 CHOLANGIOPANCREATOGRAPHY	137
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)	138
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)	138
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC)	138
9.2.5 POSITRON EMISSION TOMOGRAPHY (PET)	138
9.2.6 OTHERS	138
9.3 BIOPSY	139
9.3.1 CT-GUIDED NEEDLE BIOPSY	140
9.3.2 FINE NEEDLE ASPIRATION (FNA)	140
9.3.3 CORE NEEDLE BIOPSY	140
9.3.4 OTHERS	140
9.4 BLOOD TEST	140
9.4.1 LIVER FUNCTION TEST	141
9.4.2 TUMOR MARKER	141
9.4.2.1 CA 19-9 BIOMARKER TEST	142
9.4.2.2 CARCINOEMBRYONIC ANTIGEN (CEA) TEST	142
9.4.2.3 CA 50 MARKER TEST	142
9.4.2.4 OTHERS	142
9.4.3 OTHERS	142
9.5 GENOMIC TEST	143
9.6 OTHERS	144
10 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES	145
10.1 OVERVIEW	146
10.2 STAGE IV	149

10.3 STAGE III	149
10.4 STAGE II	150
10.4.1 STAGE IIA	151
10.4.2 STAGE IIB	151
10.5 STAGE I	151
10.5.1 STAGE IA	152
10.5.2 STAGE IB	152
10.6 STAGE 0	153
11 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE	154
11.1 OVERVIEW	155
11.2 EXOCRINE TUMORS	158
11.2.1 INSTRUMENT-BASED PRODUCTS	159
11.2.2 PLATFORM-BASED PRODUCTS	159
11.2.3 KITS AND REAGENTS	159
11.2.4 OTHER CONSUMABLES	159
11.3 NEUROENDOCRINE TUMORS	159
11.3.1 INSTRUMENT-BASED PRODUCTS	160
11.3.2 PLATFORM-BASED PRODUCTS	160
11.3.3 KITS AND REAGENTS	161
11.3.4 OTHER CONSUMABLES	161
12 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT	162
12.1 OVERVIEW	163
12.2 INSTRUMENT-BASED PRODUCTS	166
12.2.1 IMAGING	167
12.2.2 BIOPSY	167
12.3 PLATFORM-BASED PRODUCTS	167
12.3.1 NEXT-GENERATION SEQUENCING	168
12.3.2 MICROARRAYS	168
12.3.3 PCR	168
12.3.4 OTHERS	169
12.4 KITS AND REAGENTS	169
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS	170
12.4.1.1 ELISA TEST KITS	170
12.4.1.2 CASETTE TEST KITS	170
12.4.1.3 OTHERS	170
12.4.2 CEA PANCREATIC CANCER TEST KITS	171
12.4.2.1 ELISA TEST KITS	171
12.4.2.2 CASETTE TEST KITS	171
12.4.2.3 OTHERS	171
12.5 OTHER CONSUMABLES	171
13 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY	173
13.1 OVERVIEW	174
13.2 FLUORESCENT IN SITU HYBRIDIZATION	177
13.3 NEXT GENERATION SEQUENCING	178
13.4 FLUORIMMUNOASSAY	179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION	180
13.6 IMMUNOHISTOCHEMICAL	181

13.7 OTHERS 182	
14 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183	
14.1 OVERVIEW 184	
14.2 SCREENING 187	
14.2.1 INSTRUMENT-BASED PRODUCTS 188	
14.2.2 PLATFORM-BASED PRODUCTS 188	
14.2.3 KITS AND REAGENTS 188	
14.2.4 OTHER CONSUMABLES 188	
14.3 DIAGNOSTIC AND PREDICTIVE 188	
14.3.1 INSTRUMENT-BASED PRODUCTS 189	
14.3.2 PLATFORM-BASED PRODUCTS 189	
14.3.3 KITS AND REAGENTS 189	
14.3.4 OTHER CONSUMABLES 189	
14.4 PROGNOSTIC 190	
14.4.1 INSTRUMENT-BASED PRODUCTS 191	
14.4.2 PLATFORM-BASED PRODUCTS 191	
14.4.3 KITS AND REAGENTS 191	
14.4.4 OTHER CONSUMABLES 191	
14.5 RESEARCH 191	
14.5.1 INSTRUMENT-BASED PRODUCTS 192	
14.5.2 PLATFORM-BASED PRODUCTS 192	
14.5.3 KITS AND REAGENTS 192	
14.5.4 OTHER CONSUMABLES 192	
15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193	
15.1 OVERVIEW 194	
15.2 HOSPITALS 197	
15.3 DIAGNOSTIC CENTERS 197	
15.4 CANCER RESEARCH CENTERS 198	
15.5 ACADEMIC INSTITUTES 199	
15.6 AMBULATORY SURGICAL CENTERS 200	
15.7 OTHERS 201	
16 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202	
16.1 OVERVIEW 203	
16.2 DIRECT TENDER 206	
16.3 RETAIL SALES 207	
16.4 OTHERS 208	
17 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209	
17.1 NORTH AMERICA 210	
17.1.1 U.S. 224	
17.1.2 CANADA 233	
17.1.3 MEXICO 242	
18 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 251	
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 251	
19 SWOT ANALYSIS 252	
20 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 253	
20.1 CANON MEDICAL SYSTEMS CORPORATION 253	
20.1.1 COMPANY SNAPSHOT 253	

20.1.2 REVENUE ANALYSIS	253
20.1.3 COMPANY SHARE ANALYSIS	254
20.1.4 PRODUCT PORTFOLIO	254
20.1.5 RECENT DEVELOPMENT	254
20.2 KONINKLIJKE PHILIPS N.V.	255
20.2.1 COMPANY SNAPSHOT	255
20.2.2 REVENUE ANALYSIS	255
20.2.3 COMPANY SHARE ANALYSIS	256
20.2.4 PRODUCT PORTFOLIO	256
20.2.5 RECENT DEVELOPMENTS	256
20.3 SIEMENS HEALTHCARE GMBH	258
20.3.1 COMPANY SNAPSHOT	258
20.3.2 REVENUE ANALYSIS	258
20.3.3 COMPANY SHARE ANALYSIS	259
20.3.4 PRODUCT PORTFOLIO	259
20.3.5 RECENT DEVELOPMENT	260
20.4 GRAIL	261
20.4.1 COMPANY PROFILE	261
20.4.2 COMPANY SHARE ANALYSIS	261
20.4.3 PRODUCT PORTFOLIO	262
20.4.4 RECENT DEVELOPMENT	262
20.5 MYRIAD GENETICS, INC.	263
20.5.1 COMPANY SNAPSHOT	263
20.5.2 REVENUE ANALYSIS	263
20.5.3 COMPANY SHARE ANALYSIS	264
20.5.4 PRODUCT PORTFOLIO	264
20.5.5 RECENT DEVELOPMENT	264
20.6 BD	265
20.6.1 COMPANY SNAPSHOT	265
20.6.2 REVENUE ANALYSIS	265
20.6.3 PRODUCT PORTFOLIO	266
20.6.4 RECENT DEVELOPMENT	266
20.7 BODITECH MED INC.	267
20.7.1 COMPANY PROFILE	267
20.7.2 PRODUCT PORTFOLIO	267
20.7.3 RECENT DEVELOPMENT	267
20.8 ABBOTT (2022)	268
20.8.1 COMPANY SNAPSHOT	268
20.8.2 REVENUE ANALYSIS	268
20.8.3 PRODUCT PORTFOLIO	269
20.8.4 RECENT DEVELOPMENT	269
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION	270
20.9.1 COMPANY SNAPSHOT	270
20.9.2 REVENUE ANALYSIS	270
20.9.3 PRODUCT PORTFOLIO	271
20.9.4 RECENT DEVELOPMENT	271
20.10 ACCUBIOTECH CO., LTD.	272

20.10.1 COMPANY PROFILE	272
20.10.2 PRODUCT PORTFOLIO	272
20.10.3 RECENT DEVELOPMENTS	272
20.11 AGILENT TECHNOLOGIES, INC.	273
20.11.1 COMPANY PROFILE	273
20.11.2 REVENUE ANALYSIS	273
20.11.3 PRODUCT PORTFOLIO	274
20.11.4 RECENT DEVELOPMENT	274
20.12 CREATIVE BIOLABS.	275
20.12.1 COMPANY PROFILE	275
20.12.2 PRODUCT PORTFOLIO	275
20.12.3 RECENT DEVELOPMENT	275
20.13 CTK BIOTECH, INC.	276
20.13.1 COMPANY PROFILE	276
20.13.2 PRODUCT PORTFOLIO	276
20.13.3 RECENT DEVELOPMENT	276
20.14 DIASOURCE	277
20.14.1 COMPANY SNAPSHOT	277
20.14.2 PRODUCT PORTFOLIO	277
20.14.3 RECENT DEVELOPMENT	277
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS	278
20.15.1 COMPANY SNAPSHOT	278
20.15.2 REVENUE ANALYSIS	278
20.15.3 PRODUCT PORTFOLIO	279
20.15.4 RECENT DEVELOPMENTS	279
20.16 LEE BIOSCIENCE	280
20.16.1 COMPANY SNAPSHOT	280
20.16.2 PRODUCT PORTFOLIO	280
20.16.3 RECENT DEVELOPMENT	280
20.17 MERIDIAN BIOSCIENCE INC.	281
20.17.1 COMPANY PROFILE	281
20.17.2 PRODUCT PORTFOLIO	281
20.17.3 RECENT DEVELOPMENT	281

NA Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 292 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*
<input type="text"/>	<input type="text"/>
First Name*	Last Name*
<input type="text"/>	<input type="text"/>
Job title*	
<input type="text"/>	
Company Name*	EU Vat / Tax ID / NIP number*
<input type="text"/>	<input type="text"/>
Address*	City*
<input type="text"/>	<input type="text"/>
Zip Code*	Country*
<input type="text"/>	<input type="text"/>
	Date
	<input type="text" value="2026-02-10"/>
	Signature
	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com